Device Trial Radar · NCT07174622
Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Oct 28, 2025
Primary completion
Jun 2029
Study completion Jun 2029
Sponsor
- Lead sponsor
- Medtronic VascularPublic (MDT)
- Sponsor type
- Industry
- First posted
- Sep 16, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This observational study will assess the long-term effectiveness of the RDN procedure for lowering blood pressure in Medicare patients with uncontrolled hypertension. This research will be conducted using de-identified electronic health records (EHR) and administrative health insurance claims data. Patients are enrolled through the submission of claims or encounter data to CMS.
Conditions
- Hypertension
- Cardiovascular Diseases
- Vascular Diseases
Interventions
Renal Denervation (Symplicity Spyral™)Device
Symplicity Spyral™ multi-electrode renal denervation system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Office Systolic Blood Pressure (OSBP)Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.